Off-Label Promotion Settlement Includes Optional Preclearance Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Amarin may submit up to two proposed communications annually about unapproved use of Vascepa, and FDA must respond with any concerns within 60 calendar days.